For instance, MSB0011359C, a novel drug composed of the fusion of a monoclonal antibody targeting PD-L1 and a protein containing the extracellular domain of TGFB type II receptor, significantly improves the ability of immune cells to kill tumor cells, overcoming the resistance of tumor cells to PD-1/PD-L1 therapy. Here, PDCD1 is linked to neoplasm.